Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Episode | Date |
---|---|
Discussing the Role of MRD in CLL With Talal Hilal, MD
|
May 16, 2024 |
‘The HemOnc Pulse’ Live 2024: How Is Hodgkin Lymphoma Treated?
|
May 14, 2024 |
Unanswered Questions in MDS at ‘The HemOnc Pulse’ Live 2024 in Chicago
|
May 13, 2024 |
‘The HemOnc Pulse Live’ in Chicago: Fellows Discuss Choosing a Career Path in Hematology Oncology
|
May 08, 2024 |
“The HemOnc Pulse” Live 2024 in Chicago: CAR-T Unanswered Questions
|
May 04, 2024 |
"The HemOnc Pulse" Live 2024 in Chicago: AML Unanswered Questions
|
May 04, 2024 |
What are the Controversies Surrounding MRD in Blood Cancers?
|
Apr 25, 2024 |
HMAs Are ‘Cornerstone’ of High-Risk MDS Treatment, Says Jamile Shammo, MD
|
Apr 10, 2024 |
Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL
|
Apr 04, 2024 |
Aaron Goodman, MD, Tells Us the 'Crux' of Castleman Disease
|
Apr 02, 2024 |
Is MRD Negativity the New Benchmark in ALL Treatment Strategies?
|
Mar 14, 2024 |
Part Two: Drs. Dahiya, Spiegel Return to Discuss 'Black Box' Warning on CAR-T Therapies
|
Feb 29, 2024 |
Dr. Coombs Spotlights Recent CHIP Updates
|
Feb 15, 2024 |
Drs. Dahiya, Spiegel Discuss CAR-T Secondary Malignancies Risk
|
Feb 08, 2024 |
Aditi Shastri, MD: Clinicians Need to ‘Come Together’ on TP53-Mutated MDS
|
Jan 18, 2024 |
What It Takes to Harmonize the World’s Hodgkin Lymphoma Data
|
Jan 04, 2024 |
Dr. Usmani Discusses Perseus, IsKia, Data Plus More Myeloma Updates
|
Dec 18, 2023 |
Dr. Venugopal Offers Her Thoughts on the Latest MDS News
|
Dec 18, 2023 |
Jerald Radich, MD: AML Abstracts to Keep an Eye on at ASH 2023
|
Dec 17, 2023 |
Inside the FDA ODAC ’Yes’ Vote to Polivy
|
Nov 30, 2023 |
Kami Maddocks, MD, on the Shocking Ibrutinib Withdrawal
|
Nov 16, 2023 |
Jorge Cortes, MD, on Why Balance Is Key in CML Therapy
|
Nov 02, 2023 |
What Are the Top Questions in ALL?
|
Oct 19, 2023 |
The ABCs of MM Treatment According to Rafael Fonseca, MD
|
Oct 05, 2023 |
The Post-POLARIX Trial Era: Polatuzumab Vedotin Shifts DLBCL Treatment
|
Sep 14, 2023 |
Dr. Garcia-Manero on the Data Behind the Luspatercept Approval
|
Sep 13, 2023 |
Mazyar Shadman, MD, MPH, Reports the Latest BTKi News in CLL
|
Aug 24, 2023 |
Bhavana Bhatnagar, MD, on the Molecular Revolution in AML
|
Aug 10, 2023 |
Do Venetoclax Combinations Trump Chemotherapy in Frontline CLL Treatment?
|
Jul 27, 2023 |
Why Grzegorz Nowakowski, MD, Says There’s a ‘Revolution’ in LBCL Therapy
|
Jul 13, 2023 |
An Expert’s Look into the World of Rare Blood Cancers
|
Jun 29, 2023 |
The Logistics of CAR-T in Hematologic Malignancies
|
Jun 15, 2023 |
Abi Vijenthira, MD, and Anca Prica, MD, on Why Certain DLBCL Therapies May Not Be Cost Effective
|
May 18, 2023 |
Sagar Lonial, MD, FACP, on Why This MRD Approach Is ’Premature’ in MM
|
May 04, 2023 |
Alan Skarbnik, MD, Gives the Lowdown on Treating Patients with Follicular Lymphoma
|
Apr 20, 2023 |
Amer Zeidan, MBBS, MHS, on the Evolution of AML Classification, Treatment
|
Apr 06, 2023 |
What Is the Cost-Effectiveness of Pola-R-CHP in DLBCL?
|
Mar 23, 2023 |
Graham Collins, MBBS, on New Agents, Prognostic Models in Hodgkin Lymphoma
|
Mar 09, 2023 |
What Keeps Michael Bishop, MD, Up at Night When it Comes to CAR-T?
|
Feb 23, 2023 |
Laurie H. Sehn, MD, MPH, on the Game-Changing Bispecifics in Follicular Lymphoma
|
Feb 09, 2023 |
Sanam Loghavi, MD, Tells Us Why 2022 was a Major Year for MDS
|
Jan 26, 2023 |
Elizabeth Brem, MD, on Which CLL Abstract From ASH 2022 Can’t Be Ignored
|
Jan 12, 2023 |
Ruben Mesa, MD, Discusses MPN Updates at ASH 2022 and the Evolution of the Disease
|
Dec 29, 2022 |
Drs. Hagop Kantarjian and Elias Jabbour Discuss Important AML, ALL Updates From ASH 2022
|
Dec 14, 2022 |